Shanghai-based Bide Pharmatech Co., Ltd, a specialist in drug building blocks, is set to make an initial public offering (IPO) of 16 million shares on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR), raising an estimated RMB 43.44 million (USD 6.2 million). The move marks a significant milestone for the company as it seeks to expand its market presence and enhance its R&D capabilities.<\/p>\n\n\n\n
Company Background and Focus<\/strong>
Bide’s products are primarily used in the research and development of new molecular entities (NMEs) for pharmaceutical companies. Over the period from 2007 to 2019, the firm has secured a growing number of NMEs, with a particular focus on rare diseases rather than the oncology field. Bide specializes in the early stages of novel drug R&D, providing a wide variety of high-end drug molecular building blocks and scientific reagents with novel structures. These products cover the entire spectrum from drug target discovery, hit compound screening, lead compound generation and optimization, to clinical candidate drug selection.<\/p>\n\n\n\n